Global Non-Invasive Cancer Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

Global Non-Invasive Cancer Diagnostics Market 2024 by Company, Regions, Type and Application, Forecast to 2030

According to our (Global Info Research) latest study, the global Non-Invasive Cancer Diagnostics market size was valued at USD 111670 million in 2023 and is forecast to a readjusted size of USD 144320 million by 2030 with a CAGR of 3.7% during review period.

Global non invasive cancer diagnostics and technologies market is anticipated to show lucrative growth over the forecast period owing to factor such as rising demand for minimally invasive therapeutics and diagnosis for the treatment of cancer. Moreover, increasing prevalence of cancer because of rising aging population and unhealthy lifestyle is also important factor that is fueling the growth of this market. Commercialization of non invasive cancer diagnostics and technologies is expected to grow owing to completion of human genome project (HGP) which will help in identifying chemical base pairs which make up DNA, hence opening avenues for market players. Rising awareness amongst people about the advantages of early diagnosis and treatment of cancer has led to a hike in number of people undergoing diagnosis. Furthermore, growing research and development in cancer diagnosis and treatment is another factor that is boosting the growth. Advancements in cancer detection technologies like cancer biomarkers and fluorescence in situ hybridization (FISH) technique are also expected to contribute towards the growth of this market.

The global non invasive cancer diagnostics and technologies market is segmented into type and technology. Based on type this market is further sub segmented into breast cancer, blood cancer, lung cancer and solid tumors. Breast cancer held the largest share in 2014 owing to factor such as increasing incidence of breast cancer. Moreover, rising awareness amongst people about symptoms, diagnosis and therapies about breast cancer has contributed towards the dominance of this segment. Also, government and non-government organization’s (NGO) initiatives to create awareness about breast cancer early diagnosis and treatment are also helping to grow this market. Breast cancer segment is also expected to witness lucrative growth over the coming seven years as a consequence of advancements like lumpectomy and partial mastectomy. Based on technology the market is segmented into immunochemistry, molecular diagnosis and clinical chemistry. Molecular diagnostic market held the largest share in 2014 as a consequence of various advantages associated to it. These advantages include high precision of diagnosis such as high specificity, high sensitivity, and rapid turnaround time.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The Global Info Research report includes an overview of the development of the Non-Invasive Cancer Diagnostics industry chain, the market status of Blood (CTCs, CTNAS), Urine (CTCs, CTNAS), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Non-Invasive Cancer Diagnostics.

Regionally, the report analyzes the Non-Invasive Cancer Diagnostics markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Non-Invasive Cancer Diagnostics market, with robust domestic demand, supportive policies, and a strong manufacturing base.

Key Features:

The report presents comprehensive understanding of the Non-Invasive Cancer Diagnostics market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Non-Invasive Cancer Diagnostics industry.

The report involves analyzing the market at a macro level:

Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., CTCs, CTNAS).

Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Non-Invasive Cancer Diagnostics market.

Regional Analysis: The report involves examining the Non-Invasive Cancer Diagnostics market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.

Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Non-Invasive Cancer Diagnostics market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.

The report also involves a more granular approach to Non-Invasive Cancer Diagnostics:

Company Analysis: Report covers individual Non-Invasive Cancer Diagnostics players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.

Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Non-Invasive Cancer Diagnostics This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Blood, Urine).

Technology Analysis: Report covers specific technologies relevant to Non-Invasive Cancer Diagnostics. It assesses the current state, advancements, and potential future developments in Non-Invasive Cancer Diagnostics areas.

Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Non-Invasive Cancer Diagnostics market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.

Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.

Market Segmentation

Non-Invasive Cancer Diagnostics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.

Market segment by Type
CTCs
CTNAS
Exosomes

Market segment by Application
Blood
Urine
Saliva

Market segment by players, this report covers
Gen-Probe Inc
Digene Corporation
Quest Diagnostics Inc
Cancer, Genetics Inc
BIOVIEW Inc
AVIVA Biosciences Corporation
Laboratory Corporation of America Holdings (LabCorp)
A&G Pharmaceutical
Affymetrix Inc
Precision Therapeutics

Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
South America (Brazil, Argentina and Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Non-Invasive Cancer Diagnostics product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Non-Invasive Cancer Diagnostics, with revenue, gross margin and global market share of Non-Invasive Cancer Diagnostics from 2019 to 2024.

Chapter 3, the Non-Invasive Cancer Diagnostics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2019 to 2030.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Non-Invasive Cancer Diagnostics market forecast, by regions, type and application, with consumption value, from 2025 to 2030.

Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Non-Invasive Cancer Diagnostics.

Chapter 13, to describe Non-Invasive Cancer Diagnostics research findings and conclusion.